Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2007 1
2009 2
2010 2
2011 1
2012 3
2013 6
2014 6
2015 11
2016 6
2017 5
2018 5
2019 5
2020 2
2021 7
2022 6
2023 4
2024 7
2025 8
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Spatial predictors of immunotherapy response in triple-negative breast cancer.
Wang XQ, Danenberg E, Huang CS, Egle D, Callari M, Bermejo B, Dugo M, Zamagni C, Thill M, Anton A, Zambelli S, Russo S, Ciruelos EM, Greil R, Győrffy B, Semiglazov V, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Biasi O, Seitz RS, Valagussa P, Viale G, Gianni L, Bianchini G, Ali HR. Wang XQ, et al. Among authors: callari m. Nature. 2023 Sep;621(7980):868-876. doi: 10.1038/s41586-023-06498-3. Epub 2023 Sep 6. Nature. 2023. PMID: 37674077 Free PMC article.
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations.
Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, de Azambuja E, Isacke CM, Harbeck N, Kaidar-Person O, Marangoni E, Offersen BV, Rugo HS, Salvestrini V, Visani L, Morandi A, Lambertini M, Poortmans P, Livi L; Consensus Panellist Group. Meattini I, et al. Lancet Oncol. 2024 Feb;25(2):e73-e83. doi: 10.1016/S1470-2045(23)00534-X. Lancet Oncol. 2024. PMID: 38301705 Review.
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.
Rueda OM, Sammut SJ, Seoane JA, Chin SF, Caswell-Jin JL, Callari M, Batra R, Pereira B, Bruna A, Ali HR, Provenzano E, Liu B, Parisien M, Gillett C, McKinney S, Green AR, Murphy L, Purushotham A, Ellis IO, Pharoah PD, Rueda C, Aparicio S, Caldas C, Curtis C. Rueda OM, et al. Among authors: callari m. Nature. 2019 Mar;567(7748):399-404. doi: 10.1038/s41586-019-1007-8. Epub 2019 Mar 13. Nature. 2019. PMID: 30867590 Free PMC article.
Clonal Decomposition and DNA Replication States Defined by Scaled Single-Cell Genome Sequencing.
Laks E, McPherson A, Zahn H, Lai D, Steif A, Brimhall J, Biele J, Wang B, Masud T, Ting J, Grewal D, Nielsen C, Leung S, Bojilova V, Smith M, Golovko O, Poon S, Eirew P, Kabeer F, Ruiz de Algara T, Lee SR, Taghiyar MJ, Huebner C, Ngo J, Chan T, Vatrt-Watts S, Walters P, Abrar N, Chan S, Wiens M, Martin L, Scott RW, Underhill TM, Chavez E, Steidl C, Da Costa D, Ma Y, Coope RJN, Corbett R, Pleasance S, Moore R, Mungall AJ, Mar C, Cafferty F, Gelmon K, Chia S; CRUK IMAXT Grand Challenge Team; Marra MA, Hansen C, Shah SP, Aparicio S. Laks E, et al. Cell. 2019 Nov 14;179(5):1207-1221.e22. doi: 10.1016/j.cell.2019.10.026. Cell. 2019. PMID: 31730858 Free PMC article.
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.
Bosi C, Bartha Á, Galbardi B, Notini G, Naldini MM, Licata L, Viale G, Mariani M, Pistilli B, Ali HR, André F, Piras M, Callari M, Barreca M, Locatelli A, Viganò L, Criscitiello C, Pusztai L, Curigliano G, Győrffy B, Dugo M, Bianchini G. Bosi C, et al. Among authors: callari m. Eur J Cancer. 2023 Dec;195:113379. doi: 10.1016/j.ejca.2023.113379. Epub 2023 Oct 11. Eur J Cancer. 2023. PMID: 37913680 Free article.
Single-cell genomic variation induced by mutational processes in cancer.
Funnell T, O'Flanagan CH, Williams MJ, McPherson A, McKinney S, Kabeer F, Lee H, Salehi S, Vázquez-García I, Shi H, Leventhal E, Masud T, Eirew P, Yap D, Zhang AW, Lim JLP, Wang B, Brimhall J, Biele J, Ting J, Au V, Van Vliet M, Liu YF, Beatty S, Lai D, Pham J, Grewal D, Abrams D, Havasov E, Leung S, Bojilova V, Moore RA, Rusk N, Uhlitz F, Ceglia N, Weiner AC, Zaikova E, Douglas JM, Zamarin D, Weigelt B, Kim SH, Da Cruz Paula A, Reis-Filho JS, Martin SD, Li Y, Xu H, de Algara TR, Lee SR, Llanos VC, Huntsman DG, McAlpine JN; IMAXT Consortium; Shah SP, Aparicio S. Funnell T, et al. Nature. 2022 Dec;612(7938):106-115. doi: 10.1038/s41586-022-05249-0. Epub 2022 Oct 26. Nature. 2022. PMID: 36289342 Free PMC article.
Predicting and Understanding Cancer Response to Treatment.
Callari M, Gandellini P, Skvortsova I, Span PN. Callari M, et al. Dis Markers. 2018 May 29;2018:6159214. doi: 10.1155/2018/6159214. eCollection 2018. Dis Markers. 2018. PMID: 30002742 Free PMC article. No abstract available.
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.
Dugo M, Huang CS, Egle D, Bermejo B, Zamagni C, Seitz RS, Nielsen TJ, Thill M, Antón-Torres A, Russo S, Ciruelos EM, Schweitzer BL, Ross DT, Galbardi B, Greil R, Semiglazov V, Gyorffy B, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Blasi O, Callari M, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. Dugo M, et al. Among authors: callari m. Clin Cancer Res. 2024 Nov 1;30(21):4900-4909. doi: 10.1158/1078-0432.CCR-24-0149. Clin Cancer Res. 2024. PMID: 39308141 Free PMC article. Clinical Trial.
A comprehensive luminal breast cancer patient-derived xenografts (PDX) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4/6 inhibitors.
Segatto I, Mattevi MC, Rampioni Vinciguerra GL, Crestan N, Musco L, Favero A, Dall'Acqua A, Di Giustino G, Mungo G, D'Andrea S, Gava C, Ruggiero F, Dugo M, Gerratana L, Puglisi F, Massarut S, Bomben R, Callari M, Perin T, Baldassarre G, Belletti B. Segatto I, et al. Among authors: callari m. J Pathol. 2024 Dec;264(4):434-447. doi: 10.1002/path.6358. Epub 2024 Oct 25. J Pathol. 2024. PMID: 39449657
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies.
Callari M, Dugo M, Barreca M, Győrffy B, Galbardi B, Vigano L, Locatelli A, Dall'Ara C, Ferrarini M, Bisagni G, Colleoni M, Mansutti M, Zamagni C, Del Mastro L, Zambelli S, Frassoldati A, Biasi O, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. Callari M, et al. Nat Commun. 2025 Mar 4;16(1):2195. doi: 10.1038/s41467-025-57293-9. Nat Commun. 2025. PMID: 40038334 Free PMC article. Clinical Trial.
83 results